Apogee Therapeutics Inc (APGE) concluded trading on Wednesday at a closing price of $49.21, with 0.45 million shares of worth about $22.3 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.64% during that period and on January 08, 2025 the price saw a loss of about -0.73%. Currently the company’s common shares owned by public are about 45.02M shares, out of which, 36.30M shares are available for trading.
Stock saw a price change of 8.63% in past 5 days and over the past one month there was a price change of -1.52%. Year-to-date (YTD), APGE shares are showing a performance of 8.63% which increased to 66.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.05 but also hit the highest price of $72.29 during that period. The average intraday trading volume for Apogee Therapeutics Inc shares is 434.54K. The stock is currently trading 4.65% above its 20-day simple moving average (SMA20), while that difference is down -0.22% for SMA50 and it goes to -0.54% lower than SMA200.
Apogee Therapeutics Inc (NASDAQ: APGE) currently have 45.02M outstanding shares and institutions hold larger chunk of about 80.62% of that.
The stock has a current market capitalization of $2.88B and its 3Y-monthly beta is at 2.27. It has posted earnings per share of -$2.73 in the same period. It has Quick Ratio of 16.39 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APGE, volatility over the week remained 4.69% while standing at 6.34% over the month.
Analysts are in expectations that Apogee Therapeutics Inc (APGE) stock would likely to be making an EPS of -1.07 in the current quarter, while forecast for next quarter EPS is -1.1 and it is -4.06 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.28 which is -0.91 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 7.87% while it is estimated to decrease by -39.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Canaccord Genuity on November 25, 2024 offering a Buy rating for the stock and assigned a target price of $89 to it. Coverage by BofA Securities stated Apogee Therapeutics Inc (APGE) stock as a Buy in their note to investors on May 10, 2024, suggesting a price target of $80 for the stock. On December 20, 2023, BTIG Research Initiated their recommendations, while on August 08, 2023, Wedbush Initiated their ratings for the stock with a price target of $40. Stock get an Outperform rating from TD Cowen on August 08, 2023.
